Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:" Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. | Bateman et al. Respiratory Research 2011 12 38 http content 12 1 38 RESPIRATORY RESEARCH RESEARCH Open Access Overall asthma control achieved with budesonide formoterol maintenance and reliever therapy for patients on different treatment steps Cr i n D s 4- m s V 1n A I_I s rr I r z 2 c I r C hi lirz-z 3 I_lz Jz z 1 Dz z J Z 1 f I4 Dev I Z 1 Oi ikl5 I_Il I m n r 6 tric D Bateman 11m W Harrison Santiago Quirce Helen K Reddei Roland Buhl Marc Humbert Hrici ino D lonlzinc4 CtofSn Doforcnn7 milio mcfli mrl7 Dtii il l l rVRwmo8 h l lfmlm D Qosirc8 nnl CiSrun c Bril ccon7 9 Cinisune R Jenkins Stefan Peteison Ollie stiund Paul M OByine Maicoim R Sears ano GOian S tiiksson Abstract Background Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing Oudesonide formoterol BUD FORM maintenance and reliever therapy Symbicort SMART Turbuhaler in patients previously prescribed treatments from Global Initiative for Asthma GINA Steps 2 3 or 4. Methods This is a post hoc analysis of the results of five large clinical trials 12000 patients comparing BUD FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined. Results At each GINA treatment step the proportion of patients achieving target levels of current clinical control were similar or higher with BUD FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid long-acting p2-agonist ICS LABA plus short-acting p2-agonist SABA as reliever and rates of exacerbations were lower at all treatment steps in BUD FORM maintenance and reliever therapy versus same maintenance dose ICS LABA P and at treatment Step 4 versus higher .
